Aug11, 2022, Shanghai, China： Maxinovel Pharmaceuticals Co., Ltd. (“Maxinovel” hereafter) announced dosing of first patient with MAX-40279 (multi-tyrosine kinase inhibitor developed by Maxinovel)in combination with KN046 (PD-L1/CTLA-4 bispecific antibody from Alphamab Oncology [stock code: 9966.HK]) in the Phase I/II study (NCT05425602) for solid tumor, at the Cancer Hospital of the University of Chinese Academy of Sciences (Zhejiang Cancer Hospital), Hangzhou, China.
August 8, 2022, Shanghai, China: Maxinovel Pharmaceuticals Co., Ltd. (“Maxinovel” hereafter) announced dosing of first patient with MAX-40279, a novel multi-tyrosine kinase inhibitor developed by Maxinovel, combined with toripalimab (Anti-PD-1 monoclonal antibody) in the multi-center Phase I study (NCT05369286) for advanced solid tumor at the Sixth Affiliated Hospital of Sun Yat-sen University, Guangzhou, China.
July 7, 2022, Shanghai, China: Maxinovel Pharmaceuticals Co., Ltd. (“Maxinovel” hereafter) announced dosing of first patient with MAX-40279, a novel multi-tyrosine kinase inhibitor developed by Maxinovel, in the multi-center Phase II study (MAX-40279-006, NCT05395780) of 2nd line or above therapy for advanced gastric cancer or gastroesophageal junction cancer, at the Nanjing Drum Tower Hospital (also named as the Affiliated Hospital of Nanjing University Medical School), Jiangsu, China.
April 28, 2022, Shanghai, China: Maxinovel Pharmaceuticals Co., Ltd. (“Maxinovel” hereafter) announced dosing of first patient with MAX-40279, a novel multi-tyrosine kinase inhibitor developed by Maxinovel, in the global multi-center Phase II study (MAX-40279-005, NCT05130021) of 3rd line or above therapy for advanced colorectal cancer, at the Sixth Affiliated Hospital of Sun Yat-sen University, Guangzhou, China.
京公網安備11011502038449號
